Peptide Profile
Semaglutide is a peptide-based GLP-1 receptor agonist. The molecule is modified to provide a longer pharmacological action than native GLP-1. Within this research catalogue, Semaglutide is described solely as a peptide profile for scientific documentation.
What is it?
Semaglutide is a peptide-based GLP-1 receptor agonist. The molecule is modified to provide a longer pharmacological action than native GLP-1. Within this research catalogue, Semaglutide is described solely as a peptide profile for scientific documentation.
Receptor profile
Its central receptor target is the GLP-1 receptor. GLP-1 is an endogenous peptide hormone and part of a signalling pathway studied in metabolic and endocrine research.
Scientific status
Semaglutide is no longer an experimental active ingredient: medicinal products containing Semaglutide have regulatory approvals. A research material in this catalogue must therefore be clearly distinguished from an approved finished medicinal product.
Peptide analytics
For technical documentation of a peptide material, clear batch assignment, identity assessment and method-linked purity analysis are particularly relevant. HPLC and LC-MS are common analytical methods when they have actually been performed and documented for the specific batch.
References & studies
Official references and selected peer-reviewed studies. Study links are provided for scientific context and are not administration guidance.
Reference for regulatory status, product information and GLP-1 receptor agonism.
Open source ↗Clinical studyRandomized phase 3 trial in adults with overweight or obesity without diabetes.
Open source ↗Outcome studyRandomized cardiovascular outcome trial in adults with established cardiovascular disease and overweight or obesity without diabetes.
Open source ↗